Celgene Corporation
Feb 11, 2014
Add to Briefcase

Celgene Corporation to Present at Investor Conferences in February and March

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at three upcoming investor conferences. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.

Wednesday, February 26, 2014 at the 2014 RBC Capital Markets Healthcare Conference in New York at 11:30 a.m. ET

Tuesday, March 4, 2014 at Cowen's 34th Annual Health Care Conference in Boston at 11:20 a.m. ET

Wednesday, March 12, 2014 at the Barclays Capital Healthcare Conference in Miami at 11:15 a.m. ET

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Celgene Corporation
Jacqualyn A. Fouse, PhD, 908-673-9956
EVP, Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations

Source: Celgene Corporation

News Provided by Acquire Media